...
首页> 外文期刊>Inflammatory bowel diseases >Intestinal Fibrosis in Crohn's Disease: Role of microRNAs as Fibrogenic Modulators, Serum Biomarkers, and Therapeutic Targets
【24h】

Intestinal Fibrosis in Crohn's Disease: Role of microRNAs as Fibrogenic Modulators, Serum Biomarkers, and Therapeutic Targets

机译:克罗恩病肠道纤维化:microRNA作为纤维生成调节剂,血清生物标志物和治疗靶标的作用

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Inflammation often precedes fibrosis and stricture formation in patients with Crohn's disease. Established medical therapies reduce inflammation, but there are currently no specific therapies to prevent fibrosis or treat established fibrosis. Our understanding of the pathogenic processes underpinning fibrogenesis is limited compared with our knowledge of the events initiating and propagating inflammation. There are several biomarkers for intestinal inflammation, but there are none that reflect the development of fibrosis. MicroRNAs (miRNAs) are regulators of cellular activities including inflammation and fibrosis and may serve as biomarkers of disease processes. Differential serum and mucosal miRNA expression profiles have been identified between patients with inflammatory bowel disease with active and inactive inflammatory disease. In contrast, studies in patients with fibrotic phenotypes are comparatively few, although specific miRNAs have defined roles in the development of fibrosis in other organ systems. Here, we discuss the most recent research on miRNA and fibrogenesis with a particular emphasis on Crohn's disease. We also anticipate the potential of miRNAs in fulfilling current unmet translational needs in this patient group by focusing on the role of miRNAs as modulators of fibrogenesis and on their potential value as serum biomarkers and therapeutic targets in the management of fibrosis.
机译:在克罗恩病患者中,炎症通常先于纤维化和狭窄形成。既定的医学疗法可减轻炎症,但目前尚无预防纤维化或治疗既定纤维化的具体疗法。与我们对引发和传播炎症的知识相比,我们对支撑纤维形成的致病过程的理解是有限的。肠道炎症有几种生物标志物,但没有一种能反映纤维化的发展。微小RNA(miRNA)是包括炎症和纤维化在内的细胞活动的调节剂,可作为疾病过程的生物标记。已经在患有活动性和非活动性炎性疾病的炎性肠病患者之间鉴定出差异的血清和粘膜miRNA表达谱。相比之下,具有纤维化表型的患者的研究相对较少,尽管特定的miRNA在其他器官系统的纤维化发展中已定义了作用。在这里,我们讨论了有关miRNA和纤维发生的最新研究,特别着重于克罗恩氏病。我们还通过关注miRNA作为纤维化发生调节剂的作用及其作为血清生物标志物和纤维化治疗靶标的潜在价值,来预测该患者组中miRNA满足当前未满足的翻译需求的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号